138356-21-5
基本信息
BD1047.2HBr
BD 1047 HBr
BD-1047
BD 1047
BD1047.2HBr(1K/g)
BD 1047 (hydrobromide)
N1-(3,4-DICHLOROPHENETHYL)-N1,N2,N2-TRIMETHYLETHANE-1,2-DIAMINE 2HBR
N1-(3,4-dichlorophenethyl)-N1,N2,N2-trimethylethane-1,2-diamine dihydrobromide
N-[2-(3,4-Dichlorophenyl)ethyl]-N,N',N'-trimethyl-1,2-ethanediamine dihydrobromide
n-[2-(3,4-dichlorophenyl)ethyl]-n,n',n'-trimethylethane-1,2-diamine dihydrobromide
物理化学性质
| 储存条件 | Inert atmosphere,2-8°C |
| 溶解度 | 在水中的溶解度>5mg/mL |
| 形态 | 粉末 |
| 颜色 | 白色 |
| 水溶解性 | H2O: >5mg/mL |
| 稳定性 | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months. |
| InChI | 1S/C13H20Cl2N2.2BrH/c1-16(2)8-9-17(3)7-6-11-4-5-12(14)13(15)10-11;;/h4-5,10H,6-9H2,1-3H3;2*1H |
| InChIKey | WOALTFHGLDVJHK-UHFFFAOYSA-N |
| SMILES | Br.Br.CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1 |
安全数据
| 危险性符号(GHS) | ![]() ![]() GHS05,GHS07 |
| 警示词 | 危险 |
| 危险性描述 | H315-H318-H335 |
| 防范说明 | P280-P302+P352-P305+P351+P338+P310 |
| 危险品标志 | Xi |
| 危险类别码 | 37/38-41 |
| 安全说明 | 26-36/37 |
| WGK Germany | 3 |
| 存储类别 | 11 - Combustible Solids |
| 危险性类别 | Eye Dam. 1 Skin Irrit. 2 STOT SE 3 |
BD-1047盐酸盐价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/09/19 | S0106 | BD-1047盐酸盐 BD-1047 dihydrobromide | 138356-21-5 | 5mg | 753.46元 |
| 2025/09/19 | S0106 | BD-1047盐酸盐 BD-1047 dihydrobromide | 138356-21-5 | 25mg | 2024.47元 |
常见问题列表
| Target | Value |
|
σ1 receptor
() |
BD-1047 (dihydrobromide) prevents that Cutamesine reduces the cell death rate induced by light exposure in murine photoreceptor-derived 661w cells.
BD-1047 (dihydrobromide) attenuates that Cutamesine reduces the mitochondrial damage and the elevated level of caspase 3/7 activity.
BD-1047 (dihydrobromide) (1-10 mg/kg; i.p.) decreases the Apomorphine (APO)-induced climbing behavior at the dose of 10 mg/kg in mice.
BD-1047 (dihydrobromide) counteracts the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine).
BD-1047 (dihydrobromide) reduces the increasing expression of pNR1, and reverses the Sig-1 R agonists potentiated NMDA-induced pain behaviour and pNR1 immunoreactivity.
| Animal Model: | Male Albino Swiss mice (50 days old, 25–28 g) |
| Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Decreased the APO-induced climbing at the dose of 10 mg/kg in mice. |

